Treatment ( for PFS only ) , younger age , confirmed absence of residual tumour on imaging , frontal location , good World Health Organisation ( WHO ) performance status , absence of endothelial abnormalities and/or necrosis , 1p/19q codeletion and Isocitrate dehydrogenase 1 ( IDH1 ) mutation were independent factors that predicted better PFS and OS .
